AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28138867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care (physiotherapy and occupational therapy) + Relational active music therapy
Number of subjects: 38
Study 28138867 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 38
Study 26497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT) with FOLFOX/CAPEOX before induction neoadjuvant chemotherapy (INCT) or after consolidation neoadjuvant chemotherapy (CNCT), with 5‐FU or capecitabine‐based chemoradiation.
Number of subjects: 0
Study 26497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective non‐operative management (NOM) for patients with clinical complete response (cCR).
Number of subjects: 0
Study 26497495 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) for patients with residual tumor at the primary site.
Number of subjects: 0
Study 23845979 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 1 hour of treadmill walking at 55-60% peak O2 uptake, performed the evening before a meal test.
Number of subjects: 28
Study 23845979 — intervention group
Group type: COMPARATOR
Intervention: No Exercise (NoEX) - control condition with no exercise prior to the meal test.
Number of subjects: 28
Study 21536947 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 90
Study 21536947 — intervention group
Group type: COMPARATOR
Intervention: midazolam (0.3 mg/kg; max 15 mg)
Number of subjects: 90
Study 21536947 — intervention group
Group type: COMPARATOR
Intervention: 10% nitrous oxide
Number of subjects: 90
Study 19142744 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported quality of life evaluations using HRQOL questionnaires (SF-36, EQ-5D, HAQ)
Number of subjects: 1331
Study 19142744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interviewing techniques and semi-structured topic guides
Number of subjects: 1331
Study 17721103 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation arm (CD4 T-cell-guided ART strategy)
Number of subjects: 5472
Study 17721103 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression arm (continuous ART)
Number of subjects: 5472
Study 17721103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 5472
Study 16946677 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital wide-angle photographic fundus screening
Number of subjects: 51
Study 16946677 — intervention group
Group type: COMPARATOR
Intervention: Bedside indirect ophthalmoscopy
Number of subjects: 51
Study 14562945 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 20 mg intramuscular injections of a preS2/S vaccine (GenHevac‐B) on days 0, 30 and 60
Number of subjects: 71
Study 14562945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine therapy)
Number of subjects: 71
Study 10477361 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 32
Study 10477361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study 8684200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP) 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776
Study 8684200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-based plasma substitute 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776
Study 8684200 — intervention group
Group type: COMPARATOR
Intervention: Glucose (control) 20 mL/kg followed by 10 mL/kg after 24 h
Number of subjects: 776
Study 1655223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 cGy RT and dactinomycin and vincristine
Number of subjects: 7
Study 1655223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 cGy RT and dactinomycin and vincristine
Number of subjects: 7
Study 1655223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 cGy RT and dactinomycin, vincristine, and doxorubicin
Number of subjects: 7
Study 1655223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 cGy RT and dactinomycin, vincristine, and doxorubicin
Number of subjects: 7
Study 6760980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg nocte)
Number of subjects: 75
Study 6760980 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen (2-3 mg per day in three administrations)
Number of subjects: 75
Study 29528499 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg daily
Number of subjects: 0
Study 29528499 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600 mg daily
Number of subjects: 0
Study 29528499 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 0
Study 27464860 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 μg/kg
Number of subjects: 95
Study 27464860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 140 μg/kg (Group O/70)
Number of subjects: 95
Study 27464860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 200 μg/kg (Group O/100)
Number of subjects: 95
Study 23847021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alcohol use
Number of subjects: 246
Study 23847021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anger
Number of subjects: 246
Study 23431348 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoqinglong granules (XQLG) as add-on therapy to seretide
Number of subjects: 178
Study 23431348 — intervention group
Group type: COMPARATOR
Intervention: Seretide plus placebo
Number of subjects: 178
Study 20694887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold beverage (4 °C)
Number of subjects: 7
Study 20694887 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral beverage (37 °C)
Number of subjects: 7
Study 20694887 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral + ice trial
Number of subjects: 7
Study 18633426 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 0
Study 18633426 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan high-dose combination therapy
Number of subjects: 0
Study 18633426 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 16385103 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesics
Number of subjects: 29
Study 16385103 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodologic features (slow titration, flexible dosing, minimizing concomitant analgesics, fewer study sites)
Number of subjects: 29
Study 16385103 — intervention group
Group type: EXPERIMENTAL
Intervention: Study designs with high dropout rates
Number of subjects: 29
Study 12434959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear syringing
Number of subjects: 0
Study 12434959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ear syringing)
Number of subjects: 0
Study 9890409 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg/kg bolus in 30 min and then 10 microg/kg/min for 1 h 30 min)
Number of subjects: 8
Study 9890409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 8
Study 8606901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical unweighting at 20% body weight support (BWS)
Number of subjects: 27
Study 8606901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical unweighting at 40% body weight support (BWS)
Number of subjects: 27
Study 2015727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and propranolol (80 mg) combination
Number of subjects: 8
Study 2015727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and metoprolol (100 mg) combination
Number of subjects: 8
Study 2015727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and pindolol (5 mg) combination
Number of subjects: 8
Study 2015727 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (propranolol, metoprolol, pindolol) alone
Number of subjects: 8
Study 2015727 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and beta-blocker combinations
Number of subjects: 8
Study 2015727 — intervention group
Group type: EXPERIMENTAL
Intervention: All verapamil and beta-blocker combinations
Number of subjects: 8
Study 6175885 — intervention group
Group type: EXPERIMENTAL
Intervention: Script and slides
Number of subjects: 24
Study 6175885 — intervention group
Group type: COMPARATOR
Intervention: Audiotape and slides
Number of subjects: 24
Study 6175885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 24
Study 31553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab 130 mg
Number of subjects: 961
Study 31553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab 6 mg/kg
Number of subjects: 961
Study 31553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab 90 mg every 12 weeks
Number of subjects: 961
Study 31553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab 90 mg every 8 weeks
Number of subjects: 961
Study 31553833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 961
Study 28475754 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-component intervention to increase skilled birth attendant utilization
Number of subjects: 3844
Study 28475754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3844
Study 25132411 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 25132411 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 25132411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25132411 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS usability
Number of subjects: 0
Study 23681133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC-capture stent
Number of subjects: 60
Study 23681133 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 60
Study 21700611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 5430
Study 21700611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5430
Study 19470045 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble nail lacquer applied once daily on the affected fingernails of the left hand for 24 consecutive weeks
Number of subjects: 30
Study 18063204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IP) with 0.2% ropivacaine
Number of subjects: 60
Study 18063204 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA) with ropivacaine
Number of subjects: 60
Study 12851662 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine system
Number of subjects: 60
Study 12851662 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 60
Study 10725475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 185
Study 10725475 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 185
Study 8956390 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketamine
Number of subjects: 40
Study 8956390 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 40
Study 8956390 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketamine plus 0.5 mg morphine
Number of subjects: 40
Study 8956390 — intervention group
Group type: COMPARATOR
Intervention: Control group A (10 mL saline with no additive)
Number of subjects: 40
Study 1574977 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (induced with propofol and maintained with an infusion of propofol 12 mg/kg/h for the first 15 min, followed by 8 mg/kg/h)
Number of subjects: 30
Study 1574977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (induced with propofol and maintained with isoflurane 0.5-2%)
Number of subjects: 30
Study 1574977 — intervention group
Group type: COMPARATOR
Intervention: Control (unanaesthetised)
Number of subjects: 30
Study 2932989 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 200 micrograms
Number of subjects: 8
Study 2932989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 20 mg
Number of subjects: 8
Study 2932989 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo
Number of subjects: 8
Study 2932989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 1 mg
Number of subjects: 8
Study 31141805 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐min chemical matricectomy using phenol (CMP)
Number of subjects: 622
Study 28971121 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 42
Study 28971121 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 42
Study 25864998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing and antirotator proximal femoral nail implant (TST, Turkey)
Number of subjects: 86
Study 25864998 — intervention group
Group type: COMPARATOR
Intervention: Cementless bipolar hemiarthroplasty
Number of subjects: 86
Study 23510143 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term calcium supplementation
Number of subjects: 0
Study 23510143 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat approach
Number of subjects: 0
Study 21220718 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard + Continuum curriculum
Number of subjects: 0
Study 21220718 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum alone
Number of subjects: 0
Study 19341986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50
Study 19341986 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscular relaxation
Number of subjects: 50
Study 16889855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 30
Study 15191261 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership between advanced practice nurse (APN) and volunteer peer advisor
Number of subjects: 20
Study 11157333 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched foods plus a social program
Number of subjects: 130
Study 11157333 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular foods plus exercise
Number of subjects: 130
Study 11157333 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched foods plus exercise
Number of subjects: 130
Study 11157333 — intervention group
Group type: COMPARATOR
Intervention: Regular foods plus a social program
Number of subjects: 130
Study 9890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating soluble form of Fas (sFas) in DCM
Number of subjects: 33
Study 9890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (sFas > or =2.06 ng/ml)
Number of subjects: 33
Study 9890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (sFas <2.06 ng/ml)
Number of subjects: 33
Study 9890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of circulating sFas levels
Number of subjects: 33
Study 9890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of left ventricular dimension between groups
Number of subjects: 33
Study 7625255 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 93
Study 7625255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-led intervention
Number of subjects: 93
Study 7625255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 2672998 — intervention group
Group type: EXPERIMENTAL
Intervention: buzepide metiodide and haloperidol combination
Number of subjects: 224
Study 2672998 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 224
Study 82401 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 81
Study 82401 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 81
Study 31307913 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein supplementation (2 capsules daily for 12 weeks, each containing 54 mg genistein)
Number of subjects: 54
Study 31307913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules daily for 12 weeks)
Number of subjects: 54
Study 31307913 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein group
Number of subjects: 54
Study 31307913 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 54
Study 28645227 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 10
Study 28645227 — intervention group
Group type: COMPARATOR
Intervention: Comparison practices
Number of subjects: 10
Study 25643928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with sodium tetradecyl sulfate (STS)
Number of subjects: 17
Study 25643928 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (continuation of previous treatments such as moisturization, packing, and cautery)
Number of subjects: 17
Study 23760681 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture at the footprint
Number of subjects: 57
Study 23760681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no microfracture)
Number of subjects: 57
Study 21644088 — intervention group
Group type: EXPERIMENTAL
Intervention: Videothoracoscopic surgery (VATS)
Number of subjects: 60
Study 21644088 — intervention group
Group type: COMPARATOR
Intervention: Tube thoracostomy
Number of subjects: 60
Study 19564519 — intervention group
Group type: EXPERIMENTAL
Intervention: W‐E Trial
Number of subjects: 2615
Study 19564519 — intervention group
Group type: COMPARATOR
Intervention: OVC
Number of subjects: 2615
Study 19564519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 2615
Study 16734394 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake (75 mg of isoflavone conjugates/day)
Number of subjects: 136
Study 16734394 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (45 minutes/day, 3 days/week)
Number of subjects: 136
Study 16734394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isoflavone plus walking
Number of subjects: 136
Study 16734394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 12658208 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (60 microg)
Number of subjects: 20
Study 12658208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10573618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative subcutaneous heparin (Group B, 8 patients - 4 laparoscopic and 4 open)
Number of subjects: 36
Study 10573618 — intervention group
Group type: COMPARATOR
Intervention: No preoperative thromboprophylaxis (Group A, 28 patients - 16 laparoscopic and 12 open)
Number of subjects: 36
Study 10573618 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Groups A and B
Number of subjects: 36
Study 8706070 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers and diuretics
Number of subjects: 54
Study 8706070 — intervention group
Group type: COMPARATOR
Intervention: Control group (38 men)
Number of subjects: 54
Study 1831397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA) 1000 mg i.m. daily for 15 days, followed by 1000 mg weekly
Number of subjects: 105
Study 1831397 — intervention group
Group type: COMPARATOR
Intervention: Estramustine 280 mg per os twice daily
Number of subjects: 105
Study 1831397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA)
Number of subjects: 105
Study 1831397 — intervention group
Group type: COMPARATOR
Intervention: Estramustine
Number of subjects: 105
Study 6918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 6.25 mg twice daily for 4 weeks
Number of subjects: 59
Study 6918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 12.5 mg twice daily for 4 weeks
Number of subjects: 59
Study 6918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 25 mg twice daily for 4 weeks
Number of subjects: 59
Study 6918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 50 mg twice daily for 4 weeks
Number of subjects: 59
Study 6918402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin (all doses)
Number of subjects: 59
Study 3893605 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention in families of schizophrenic patients
Number of subjects: 0
Study 3893605 — intervention group
Group type: COMPARATOR
Intervention: Regular medication (Control)
Number of subjects: 0
Study 30370632 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive coronally advanced flap (MICAF)
Number of subjects: 7
Study 30370632 — intervention group
Group type: COMPARATOR
Intervention: Modified coronally advanced flap (MCAF)
Number of subjects: 7
Study 27688266 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal characteristics (age, race, religion, religious beliefs) and external characteristics (ever sexually active, social support, type of routine HCP)
Number of subjects: 110
Study 27688266 — intervention group
Group type: EXPERIMENTAL
Intervention: Race and religious beliefs
Number of subjects: 110
Study 24439973 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (AbsorbBVS)
Number of subjects: 2690
Study 24439973 — intervention group
Group type: COMPARATOR
Intervention: XIENCE family everolimus-eluting metallic coronary stent system
Number of subjects: 2690
Study 22773179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric profile (Aberration Smart Ablation [ASA])
Number of subjects: 30
Study 22773179 — intervention group
Group type: COMPARATOR
Intervention: Non-aspheric profile (Tissue Saving Ablation [TSA])
Number of subjects: 30
Study 20398378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative fluid therapy
Number of subjects: 204
Study 20398378 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 204
Study 20398378 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intensive care
Number of subjects: 204
Study 20398378 — intervention group
Group type: COMPARATOR
Intervention: High dependency care
Number of subjects: 204
Study 18552616 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with MMC and single-layer AMT
Number of subjects: 37
Study 18552616 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with MMC alone
Number of subjects: 37